echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Corning Jerry HER2 Dual Anti-Conjugated Drug (KN026-ADC) JSKN003 completed the first patient administration in a phase I clinical study in Australia

    Corning Jerry HER2 Dual Anti-Conjugated Drug (KN026-ADC) JSKN003 completed the first patient administration in a phase I clinical study in Australia

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Corning Jereh Biopharma (Stock code: 9966.


    The study (NCT05494918) is an open, multicenter, dose-increasing Phase I clinical study to assess the safety, tolerability, and initial efficacy of JSKN003 in patients with advanced or metastatic solid tumors and to determine the recommended phase II dose (RP2D).


    Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor (EGFR/ErbB) superfamily that regulates tumor proliferation and migration


    JSKN003 is an antibody-conjugated drug (bsAb-ADC)


    Dr.


    Corning Jereh Biopharma (Stock code: 9966.


    The study (NCT05494918) is an open, multicenter, dose-increasing Phase I clinical study to assess the safety, tolerability, and initial efficacy of JSKN003 in patients with advanced or metastatic solid tumors and to determine the recommended phase II dose (RP2D).


    Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor (EGFR/ErbB) superfamily that regulates tumor proliferation and migration


    JSKN003 is an antibody-conjugated drug (bsAb-ADC)


    Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.